Enzon Pharmaceuticals, Inc. (ENZN)
Q1 2010 Earnings Call Transcript
May 10, 2010 5:00 pm ET
Craig Tooman – EVP of Finance, CFO
Alex Denner – Chairman
Ivan Horak – President, R&D and Chief Scientific Officer
Ralph Del Campo – COO
Richard Mulligan – Director
Jim Tumbering – BMO Capital Markets
Caroline Corner – William Smith & Co.
Jeffrey Cohen – C.K. Cooper & Company
Ted Wachtell – Millennium Partners
Richard Mansouri – DellaCamera Capital
Brad Gold [ph] – Capital AU Consultants [ph]
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Enzon's first quarter earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. (Operator instructions) As a reminder, this conference is being recorded.
I would now like to turn the program over to our speaker, Craig Tooman, Executive Vice President and Chief Financial Officer of Enzon Pharmaceuticals. Sir, please go ahead.
Good morning and thank you for joining us today. Very pleased to be joined on the call today by my colleagues Ralph Del Campo, our Chief Operating Officer and Dr. Ivan Horak, our President of Research and Development. We’re also pleased to have two members of our executive committee participating in our call today, our Chairman, Dr. Alex Denner and Professor, Richard Mulligan.
Let me start by reminding you that during today’s conference call, we will be making forward-looking statements that represent the company's intentions, expectations, or beliefs concerning future events. These forward-looking statements are qualified by important factors set forth in today's press release and the company's filings with the SEC, which could cause actual results to differ materially from those in such forward-looking statements. Furthermore, information discussed on today's call is accurate as of today, and we do not intend to update it.